MedRhythms On First-To-Market Track With Prescription Music Therapy For Chronic Stroke
MedRhythms’ digital therapeutics platform aims to improve walking and functional outcomes in patients with multiple sclerosis, Parkinsons’ disease and chronic stroke. With around $32m in funding to date, the start-up boasts collaborations with major medical centers and a partnership with Biogen.
You may also be interested in...
News We’re Watching: MedRhythms App Gets FDA Clearance, Recalls For Megadyne And Draeger, Elixir Stent Trial Moves Ahead
This week, companies including MedRhythms, Allergan and Urotronic announced FDA clearances; Quest and Envision launched a prostate cancer test; and the FDA designated two recalls as class I.
In this month’s Digital Health Roundup, Medtech Insight’s Reed Miller talks about Biotronik’s and AliveCor’s partnership, Marion Webb profiles three agetech companies, and Barnaby Pickering talks Swiss medtech awards and smart hospitals.
De Oro Devices’ NexStride To Help Freezing Gait Is Targeting Expansion To Other Diseases, Software Integration
De Oro Devices’ plans to add more indications for its portable device for freezing gait associated with Parkinson’s disease. In 2023, the company hopes to address multiple sclerosis, stroke and cerebral palsy, and add mobility-gait software.